Development and Optimization of Osimertinib-loaded Biodegradable Polymeric Nanoparticles Enhance In-vitro Cytotoxicity in Mutant EGFR NSCLC Cell Models and In-vivo Tumor Reduction in H1975 Xenograft Mice Models

The solid progress of nanomedicine

(2020) João Pedro Martins et al.   Drug Delivery and Translational Research

Preparation and Evaluation of Doxorubicin-Loaded PLA–PEG–FA Copolymer Containing Superparamagnetic Iron Oxide Nanoparticles (SPIONs) for Cancer Treatment: Combination Therapy with Hyperthermia and Chemotherapy

(2020) Mohammad Khaledian et al.   International Journal of Nanomedicine

Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study

(2019) Taihei Ono et al.   Thoracic Cancer

Tyrosine kinase inhibitor conjugated quantum dots for non-small cell lung cancer (NSCLC) treatment

(2019) Nishant S. Kulkarni et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice

(2019) Takashi Higuchi et al.   Translational Oncology

The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations

(2019) Puyu Shi et al.   Translational Oncology

On the issue of transparency and reproducibility in nanomedicine

(2019) Hon S. Leong et al.   Nature Nanotechnology

Calcium Chloride Modified Alginate Microparticles Formulated by the Spray Drying Process: A Strategy to Prolong the Release of Freely Soluble Drugs

(2018) Marta Szekalska et al.   Materials

Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities

(2018) Fatemeh Farjadian et al.   Nanomedicine

Osimertinib (AZD9291) increases radio‑sensitivity in EGFR T790M non‑small cell lung cancer

(2018) Nannan Wang et al.   ONCOLOGY REPORTS

Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance

(2017) Kristina B. Emdal et al.   MOLECULAR CANCER THERAPEUTICS

Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation

(2017) Arun B. et al.   Artificial Cells Nanomedicine and Biotechnology

In Vitro and In Vivo Anti-tumoral Effects of the Flavonoid Apigenin in Malignant Mesothelioma

(2017) Laura Masuelli et al.   Frontiers in Pharmacology

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

(2016) David Planchard et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer

(2016) Robert Pirker   CURRENT OPINION IN ONCOLOGY

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

(2015) D. Ercan et al.   CLINICAL CANCER RESEARCH

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed

(2015) Yuliana Yosaatmadja et al.   JOURNAL OF STRUCTURAL BIOLOGY

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of single-agent chemotherapy and targeted therapy to first-line treatment in patients aged 80 years and older with advanced non-small-cell lung cancer

(2015) Zhehai Wang et al.   OncoTargets and Therapy

EGFR gene-mutation status correlated with therapeutic decision making in lung adenocarcinoma

(2015) Yaoyao Ren et al.   OncoTargets and Therapy

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer

(2015) Toshiyuki Hirano et al.   Oncotarget

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension

(2013) Vivek Gupta et al.   JOURNAL OF CONTROLLED RELEASE

Formulation and In vitro Evaluation of Carvedilol Transdermal Delivery System

(2013) P Aparna et al.   TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2012) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Microencapsulated chitosan nanoparticles for pulmonary protein delivery: In vivo evaluation of insulin-loaded formulations

(2011) S. Al-Qadi et al.   JOURNAL OF CONTROLLED RELEASE

Formulation and Evaluation of Chitosan-Based Ampicillin Trihydrate Nanoparticles

(2011) P Saha et al.   TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH

Guidelines for the welfare and use of animals in cancer research

(2010) P Workman et al.   BRITISH JOURNAL OF CANCER

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)

(2010) Marcello Tiseo   Drug Design Development and Therapy

Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer

(2009) Anekant Jain et al.   Nanomedicine-Nanotechnology Biology and Medicine